Cargando…
The endogenous preproglucagon system is not essential for gut growth homeostasis in mice
OBJECTIVE: The prevalence of obesity and related co-morbidities is reaching pandemic proportions. Today, the most effective obesity treatments are glucagon-like peptide 1 (GLP-1) analogs and bariatric surgery. Interestingly, both intervention paradigms have been associated with adaptive growth respo...
Autores principales: | Wismann, Pernille, Barkholt, Pernille, Secher, Thomas, Vrang, Niels, Hansen, Henrik B., Jeppesen, Palle Bekker, Baggio, Laurie L., Koehler, Jacqueline A., Drucker, Daniel J., Sandoval, Darleen A., Jelsing, Jacob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485241/ https://www.ncbi.nlm.nih.gov/pubmed/28702324 http://dx.doi.org/10.1016/j.molmet.2017.04.007 |
Ejemplares similares
-
Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease
por: Hansen, Henrik H., et al.
Publicado: (2016) -
Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass
por: Barkholt, Pernille, et al.
Publicado: (2016) -
Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
por: Fabricius, Katrine, et al.
Publicado: (2017) -
The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease
por: Hansen, Henrik H., et al.
Publicado: (2015) -
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)